Elsevier

Drug and Alcohol Dependence

Volume 147, 1 February 2015, Pages 243-250
Drug and Alcohol Dependence

A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine

https://doi.org/10.1016/j.drugalcdep.2014.11.007Get rights and content

Highlights

  • Distress tolerance (DT) participants had high rates of session attendance, demonstrating feasibility.

  • DT participants had lower rates of opioid use at all follow-up assessments vs health education (HE).

  • Rates of buprenorphine dropout were 24% and 25% in the HE and DT arms, respectively.

Abstract

Background

Buprenorphine opioid agonist treatment (OAT) has established efficacy for treating opioid dependency but early relapse rates are high and are often associated with withdrawal-related or emotional distress.

Methods

To determine whether a novel distress tolerance (DT) intervention during buprenorphine initiation decreases opioid relapse, we conducted a preliminary randomized controlled trial with opioid-dependent outpatients. Participants received buprenorphine-naloxone induction and 3-months of maintenance buprenorphine plus seven, 50-min manualized, individual sessions (DT vs. health education (HE) control) over a 28-day period, linked to clinician medication dosing visits, and beginning 2 days prior to buprenorphine induction. Primary outcomes included use of illicit opioids (positive defined as any self-reported use in the prior 28 days or detected by urine toxicology) and treatment drop out.

Results

Among 49 participants, the mean age was 41 years, 65.3% were male. Persons randomized to DT had lower rates of opioid use at all three monthly assessments, and at 3-months, 72% of HE participants were opioid positive compared with 62.5% of DT participants. Rates of dropout were 24% and 25% in the HE and DT arms, respectively.

Conclusions

This distress tolerance treatment produced a small, but not statistically significant reduction in opioid use during the first three months of treatment although no differences were found in drop-out rates between conditions. If replicated in a larger study, DT could offer clinicians a useful behavioral treatment to complement the effects of buprenorphine.

Introduction

The nonmedical use of opioids, including prescription pain relievers and heroin, is a growing public health concern. In 2011, an estimated 2.2 million Americans met DSM-IV (APA, 1994) criteria for opioid abuse or dependence (Substance Abuse and Mental Health Services Administration, 2012). Buprenorphine, an opioid agonist treatment (OAT) that has been prescribed to more than a million individuals in the U.S. since it became available in 2003 (Boothby and Doering, 2007). Offered as an office-based maintenance treatment alternative to methadone, buprenorphine has demonstrated efficacy in reducing cravings, ameliorating withdrawal discomfort, and increasing periods of abstinence. In regard to treatment effectiveness (variously defined as reducing street crime, illicit drug use, HIV risk, or improving vocational development and psychological functioning), buprenorphine has long-term positive outcomes (Mattick et al., 2008). However, buprenorphine treatment drop-out rates are high, with observational studies reporting 50–65% retention rates at 6 months, and the great majority of attrition occurring during the first three months of treatment (Cunningham et al., 2008, Finch et al., 2007, Fudala et al., 2003, Lee et al., 2009, Magura et al., 2007, Mintzer et al., 2007, Soeffing et al., 2009, Stein et al., 2005).

Lapse to opioid use soon after initiation of buprenorphine is common and a strong predictor of poor treatment retention and return to chronic opioid use. Evidence from our group suggests that a significant proportion of persons initiating buprenorphine will lapse within the first week of treatment and those with a positive opioid toxicology by week four are at five times higher risk for continuing opioid use during treatment, treatment drop-out, and relapse (Stein et al., 2010). In subsequent work, we demonstrated that opioid craving, particularly during the first two weeks of buprenorphine treatment, similarly portends worse treatment outcome (Tsui et al., 2014). Thus, convergent evidence indicates that early craving and lapses to opioid use are both frequent and highly predictive of continued opioid use during buprenorphine treatment and of subsequent relapse (Stein et al., 2005, Stein et al., 2010).

Reasons for early attrition from buprenorphine treatment include inadequate dosing of buprenorphine, a desire to continue illicit drug use, social pressures due to a partner's or friend's drug use, and barriers to ongoing medication receipt such as cost and difficulty keeping medical appointments (Gryczynski et al., 2014, Mattick et al., 2008, Stein et al., 2005). However, these factors do not account for all instances of relapse. Early illicit opioid lapse despite motivation for abstinence and pharmacologic treatment of acute withdrawal with buprenorphine implicates the substantial role that early events or situations play in increasing craving and motivating drug-seeking behavior (Goldstein and Volkow, 2002, Lubman et al., 2004, Robinson and Berridge, 2001). Indeed, early recovery situations and events that are associated with emotional distress, including the sensation of inadequate opioid substitution and prolonged withdrawal symptoms, continued exposure to environmental drug cues, stresses of everyday life (e.g., financial, familial), or concurrent mood disorder symptoms, reliably induce craving among treated opioid users (Hyman et al., 2007). Indeed, negative affect is well-established as a primary precipitant of early lapse and features prominently in current models of addiction maintenance and relapse (e.g., Baker et al., 2004, Hendershot et al., 2011, Witkiewitz and Marlatt, 2004), which have informed the development of behavioral treatments unrelated to opioid agonist treatment. Skills for the management and reduction of negative affect (e.g., stress management techniques, avoidance of triggers) are primary elements of these treatments. Meta-analyses indicate that cognitive-behavioral intervention for the treatment for substance use disorder is efficacious (Magill and Ray, 2009). However, recent trials evaluating cognitive-behavioral treatment (Fiellin et al., 2013, Ling et al., 2013) and additional drug counseling (Weiss et al., 2014) have not shown significant benefit over physician management for patients taking buprenorphine (Amato et al., 2011). But earlier studies have not initiated behavioral treatment prior to buprenorphine initiation in preparation for the increased challenge of opioid withdrawal and the risk of early lapse.

Research in the area of nicotine dependence has revealed that it is not solely the severity or intensity of distress, but also one's ability to tolerate both physical and psychological distress (i.e., distress tolerance) occurring in the context of withdrawal and early abstinence that predicts whether one succumbs to a lapse (Brandon et al., 2003, Brown et al., 2002, Brown et al., 2009, Quinn et al., 1996). In these studies, distress tolerance was measured as duration of persistence on psychological and physical challenge tasks that served as analogs for the types of stresses experienced during nicotine withdrawal.

Like nicotine withdrawal and craving, acute opioid withdrawal, which is required as part of standard clinical care in the hours prior to initiating buprenorphine, and craving in the days and weeks after the initiation of buprenorphine, produce uncomfortable interoceptive symptoms such as bone and muscle aches, restlessness, and nausea. Such experiential discomfort, to a greater or lesser degree, demands the use of distress tolerance skills in order to be successful in maintaining abstinence. Evidence suggests that opioid users are overly sensitive to the discomfort associated with anxiety symptoms (Lejuez et al., 2006, Tull et al., 2007). It seems likely then, that for those opioid users initiating buprenorphine treatment who have a low threshold for tolerating distress, and/or difficulty controlling, avoiding, or suppressing the experience of distress, ongoing illicit drug use may serve as a way to manage discomfort. These illicit substance-based efforts to avoid or escape distress are maintained by negatively reinforcing effects such as the reduction of urges or negative affect, even as euphoria is blocked by the agonist properties of buprenorphine.

Supporting this hypothesis, we have recently extended findings from research on nicotine dependence to opioid dependence. The pattern of lower persistence times on the PASAT (Paced Auditory Serial Addiction Task; Diehr et al., 1998, Holdwick and Wingenfeld, 1999) showed that the probability of opioid lapse was greatest soon after initiating buprenorphine, stabilized over subsequent weeks, and was highest among those with low persistence scores (Strong et al., 2012). Given that inability or reduced ability to tolerate distress interferes with efforts to establish longer-term opioid-free behavior change (Strong et al., 2012), individuals who are initiating buprenorphine treatment may benefit from learning new skills or strategies to tolerate these withdrawal symptoms, cravings, and negative affect during early abstinence.

In the current study, we present an adaptation of a distress tolerance treatment (DT), originally developed for smokers (Brown et al., 2008, Brown et al., 2013), that was tailored for opioid dependent individuals initiating buprenorphine treatment. This treatment combines behavioral exposure to opioid craving with training in skills based in Acceptance and Commitment Therapy (Hayes, 2006) to promote maintenance of abstinence. By teaching buprenorphine initiators to minimize avoidance or efforts to escape this discomfort, treatment is meant to strengthen their ability to remain opioid abstinent. We have reported on the development piloting of a novel DT treatment for buprenorphine initiators previously (Brown et al., 2014). Based on feedback from this open trial work, we have created a treatment that we now test in a preliminary randomized trial comparing the distress tolerance treatment (DT) to a health education (HE) comparison condition.

Section snippets

Participants

Participants were recruited via advertisements (newspaper, bus). Inclusion criteria were age 18–65, seeking buprenorphine treatment, and planning to remain on buprenorphine for at least 3 months. Individuals were excluded for: current participation in methadone maintenance treatment; 15 or more days of benzodiazepine or cocaine use in the last month; daily alcohol use or binges weekly or more; medically necessary opioid treatment for chronic pain; surgery in the next 3 months; current

Results

Participants averaged 41.1 (±11.3) years of age, 32 (65.3%) were male, and 42 (85.7%) were non-Latino White (Table 1). Fourteen (28.6%) reported they had ever received prescribed buprenorphine. The mean rate of illicit opioid use in the 30 days prior to baseline was 25.2 (±7.1) days. Background characteristics were similar across groups although the HE arm tended to have a higher percentage of non-Latino Whites (92.0%) than the DT arm (79.2%).

A total of 12 participants (24.5%) dropped out of

Discussion

We tested the preliminary efficacy of a distress tolerance intervention to reduce ongoing illicit opioid use among person initiating buprenorphine treatment and found a small improvement in opioid use during the first three months of treatment compared to a health education control condition. This DT treatment incorporates elements from exposure-based and acceptance-based treatment approaches and participants demonstrated good treatment attendance by associating the behavioral intervention

Author disclosures

Role of funding source

This study was funded by the National Institute on Drug Abuse (R34 DA032767). Dr. Stein is a recipient of a NIDA Mid-Career Investigator Award (K24 DA00512). NIDA had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Contributors

Stein: Funded as PI of this award, Dr. Stein designed and implemented the study protocol, reviewed all data analysis and

References (65)

  • APA

    Diagnostic and Statistical Manual of Mental Disorders

    (1994)
  • T.B. Baker et al.

    Addiction motivation reformulated: an affective processing model of negative reinforcement

    Psychol. Rev.

    (2004)
  • J.A. Block

    Acceptance or Change of Private Experiences: A Comparative Analysis in College Students with Public Speaking Anxiety

    (2002)
  • F.W. Bond et al.

    Mediators of change in emotion-focused and problem-focused worksite stress management interventions

    J. Occup. Health Psychol.

    (2000)
  • L.A. Boothby et al.

    Buprenorphine for the treatment of opioid dependence

    Am. J. Health. Syst. Pharm.

    (2007)
  • T.H. Brandon et al.

    Pretreatment task persistence predicts smoking cessation outcome

    J. Abnorm. Psychol.

    (2003)
  • J.B. Bricker et al.

    Telephone-delivered acceptance and commitment therapy for adult smoking cessation: a feasibility study

    Nicotine Tob. Res.

    (2010)
  • R.A. Brown et al.

    A pilot study of a distress tolerance treatment for opiate-dependent patients initiating buprenorphine: rationale, methodology, and outcomes

    Behav. Modif.

    (2014)
  • R.A. Brown et al.

    Distress tolerance and duration of past smoking cessation attempts

    J. Abnorm. Psychol.

    (2002)
  • R.A. Brown et al.

    A prospective examination of distress tolerance and early smoking lapse in adult self-quitters

    Nicotine Tob. Res.

    (2009)
  • R.A. Brown et al.

    Distress tolerance treatment for early-lapse smokers: rationale, program description, and preliminary findings

    Behav. Modif.

    (2008)
  • R.A. Brown et al.

    Efficacy of Distress Tolerance/ACT Treatment vs. Standard Behavioral Treatment for Early Lapse Smokers

    (2011)
  • R.A. Brown et al.

    Development and preliminary randomized controlled trial of a distress tolerance treatment for smokers with a history of early lapse

    Nicotine Tob. Res.

    (2013)
  • M. Butler et al.

    Integration of mental health/substance abuse and primary care

    Evid. Rep. Technol. Assess. (Full Rep.)

    (2008)
  • C. Cunningham et al.

    Buprenorphine treatment in an urban community health center: what to expect

    Fam. Med.

    (2008)
  • M.C. Diehr et al.

    The Paced Auditory Serial Addition Task (PASAT): norms for age, education, and ethnicity

    Assessment

    (1998)
  • W. Fals-Stewart et al.

    The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties

    J. Consult. Clin Psychol.

    (2000)
  • D.A. Fiellin et al.

    A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine

    Am. J. Med.

    (2013)
  • D.A. Fiellin et al.

    Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence

    N. Engl. J. Med.

    (2006)
  • D.A. Fiellin et al.

    Treatment of heroin dependence with buprenorphine in primary care

    Am. J. Drug Alcohol Abuse

    (2002)
  • J.W. Finch et al.

    Two-year experience with buprenorphine–naloxone (suboxone) for maintenance treatment of opioid dependence within a private practice setting

    J. Addict. Med.

    (2007)
  • P.J. Fudala et al.

    Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone

    N. Engl. J. Med.

    (2003)
  • Cited by (24)

    • Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions

      2022, International Journal of Drug Policy
      Citation Excerpt :

      Opioid dependence is a chronic disorder characterized by high morbidity and premature mortality (Darke et al., 2006; Evans et al., 2012). Opioid agonist treatment (OAT), using methadone or buprenorphine (with/without naloxone), is a highly effective treatment for people with opioid use disorder (OUD) (Connock et al., 2007; Harris et al., 2005; Springer et al., 2010; Stein et al., 2015). OAT is also known to be associated with a 50% decrease in the number of fatal overdoses in the US (Schwartz et al., 2013; Volkow et al., 2014).

    • Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence

      2021, Drug and Alcohol Dependence
      Citation Excerpt :

      The best evidence comes from six low risk of bias (ROB) RCTs, which found that psychosocial interventions paired with standard medical management of buprenorphine was not associated with improvements in any addiction-related outcomes, including abstinence as measured by urine drug test (UDT) or retention, compared to the use of buprenorphine with standard medical management alone. In these studies, participants randomized to cognitive behavioral therapy (Fiellin et al., 2013; Ling et al., 2013), cognitive behavioral therapy paired with contingency management (Ling et al., 2013), contingency management alone (Ling et al., 2013), supportive counseling/enhanced medical management (Fiellin et al., 2006; Tetrault et al., 2012; Weiss et al., 2011) and distress tolerance treatment (Stein et al., 2015) did not evidence superior substance use outcomes over participants receiving standard medical management of buprenorphine alone. Eight additional manuscripts with greater methodological limitations examined psychosocial adjuncts to buprenorphine treatment as well.

    • Gender moderates the association between distress tolerance and alcohol use among individuals with opioid use disorder

      2018, Drug and Alcohol Dependence
      Citation Excerpt :

      Low distress tolerance predicts opioid misuse among patients with chronic pain (McHugh et al., 2016), and opioid relapse is more likely among people with low distress tolerance (Strong et al., 2012). Further, brief treatment targeting distress tolerance can result in decreases in opioid relapse among individuals with OUD (Stein et al., 2015). Individual differences in distress tolerance may be especially relevant to understanding alcohol use among individuals with OUD.

    • Endogenous Opiates and Behavior: 2015

      2017, Peptides
      Citation Excerpt :

      Equally-frequent positive and negative lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms were expressed [280]. A distress tolerance treatment reduced drug use for opioid dependent persons initiating buprenorphine [1257]. CYP450 genetic variability affected methadone dosing and tolerance in heroin-dependent patients [1319].

    View all citing articles on Scopus
    View full text